Categories
Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Description-13)

In this article we will discuss Olaparib (Description-13)

Categories
Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Description-12)

In this article, we will discuss Olaparib (Description-12). So, let’s get started. Drug Interactions (3) In vitro studies have shown that olaparib is both an inhibitor and inducer of CYP3A and an inducer of CYP2B6. Olaparib is predicted to be a weak CYP3A inhibitor in humans. In vitro studies also indicated that olaparib is an […]

Categories
Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Description-11)

In this article, we will discuss Olaparib (Description-11). So, let’s get started. Drug Interactions (2) Based on the data from a drug-interaction trial (n=22), the AUC and Cmax of olaparib decreased by 87% and 71%, respectively, when olaparib was administered in combination with rifampicin, a strong CYP3A inducer. Simulations suggested that a moderate CYP3A inducer […]

Categories
Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Description-10)

In this article, we will discuss Olaparib (Description-10). So, let’s get strarted. Drug Interactions Based on the data from a drug-interaction trial (n=57), the AUC and Cmax of olaparib increased by 170% and 42%, respectively, when Olaparib was administered in combination with itraconazole, a strong CYP3A inhibitor. Simulations suggested that a moderate CYP3A inhibitor (fluconazole) […]

Categories
Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Description-9)

In this article we will discuss Olaparib (Description-9)